Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to better understand and treat bladder cancer by using advanced computer technology called artificial intelligence (AI). The study aims to develop a system that combines information from ultrasound, MRI scans, and pathology (lab tests on tissue) to accurately determine how far the bladder cancer has spread before surgery. This is important because knowing the exact stage of cancer helps doctors choose the best treatment and avoid unnecessary procedures. The system will also try to predict how well patients might respond to chemotherapy given before surgery, which could help doctors plan more effective treatment.

People who might join this study include those who have signs of bladder cancer based on imaging tests like ultrasound or MRI and have not yet had surgery, chemotherapy, or radiation. Participants should be planning to have surgery to remove the cancer and must be able to safely receive an ultrasound contrast agent (a special dye used during the ultrasound). If you have symptoms like blood in your urine or a biopsy confirming bladder cancer, you may be eligible. During the trial, participants will undergo detailed imaging exams to help the AI system analyze the cancer. This study is currently recruiting patients of all genders and ages, and it hopes to improve future bladder cancer diagnosis and treatment decisions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ultrasound and other imaging examinations (CT, MR, etc.) suggest bladder masses and are suspicious for bladder cancer patients.
• • 2. The bladder is well filled, and no allergic reactions to ultrasound contrast agents are found.
• • 3. No surgery or radiotherapy/chemotherapy has been performed.
• 4. Patients who meet the indications for surgical resection and are planned for surgical treatment, including one of the following:
• • 1. Clinical symptoms consistent with suspected bladder cancer (such as gross hematuria, etc.);
• • 2. Patients with confirmed primary or recurrent bladder cancer by cystoscopic biopsy;
• • 3. Rapid urine cytology and urine cytology FISH testing suggest malignancy.
• Exclusion Criteria:
• • 1. Individuals unable to tolerate surgery;
• • 2. Individuals allergic to ultrasound contrast agents, unable to undergo ultrasound contrast examination;
• • 3. Unsuccessful preoperative ultrasound contrast examination or non-compliant patients;
• • 4. Postoperative pathology does not indicate bladder cancer;
• • 5. Patients who have undergone chemotherapy or radiation therapy.